期刊文献+

急性髓系白血病细胞多药耐药相关基因的筛选 被引量:2

Screening and Cloning Multi-Drug Resistance Related Gene of Acute Myeloid Leukemia Cells
下载PDF
导出
摘要 目的筛选急性髓系白血病细胞多药耐药相关基因。方法在建立HL-60/DNR多药耐药(MDR)细胞系的基础上,采用抑制消减杂交的方法结合基因芯片技术建立HL-60/DNR抑制消减杂交文库,并挑选其中部分克隆进行序列测定和同源性分析。结果HL-60/DNR对多种化疗药物均产生了不同程度的耐受。在所构建的HL-60/DNR抑制消减杂交文库中,经过基因芯片筛选出明显差异表达克隆共有14个;进一步分析发现这些基因在白血病细胞多药耐药中的作用大多未见报道。结论多种基因(已知的或未知的)均参与了急性髓系白血病细胞多药耐药的调节,大规模筛选与克隆这些基因为进一步研究急性髓系白血病细胞多药耐药产生的机制奠定了必要的理论基础。 Objective Try to screen and separate multidrug resistance (MDR) related genes in acute myeloid leukemia cell. Methods After establishing the MDR leukemia cell llne ( HL-60/DNR), a suppression subtractive hybridization library was established by suppression subtractive hybridization and gene chip. The resulting subtracted eDNA clones were partially sequenced and analyzed by blasm. Results The HL-60/DNR produced MDR to a variety of chemotherapeutic agents. 14 genes were found to express 5-fold difference of expressionlevels between HL-60/DNR and untreated HL-60 cells and were selected to sequence. Most of the 14 sequenced genes have not been reported to be related to MDR in leukemia. Conclusion Many genes both known and unknown were found to relate to the MDR in AML. Discovery of these gene provided a solid foundation to elucidate the mechanism of MDR in acute myeloid leukemia cell.
出处 《华中科技大学学报(医学版)》 CAS CSCD 北大核心 2005年第6期659-661,665,共4页 Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
基金 中国博士后科学基金资助项目(No.2004036440)
关键词 白血病 急性髓性 多药耐药 基因克隆 抑制消减杂交 基因芯片 acute myeloid leukemia multi-drug resistance gene cloning suppression subtractive hybridization gene chip
  • 相关文献

参考文献7

  • 1付劲蓉,李成荣,杨锡强,王莉佳.白血病细胞多药耐药细胞系的建立及白细胞介素4对其多药耐药的逆转研究[J].中华儿科杂志,2000,38(10):614-616. 被引量:5
  • 2杨纯正.肿瘤耐药研究的若干问题[J].中华医学杂志,2001,81(24):1475-1478. 被引量:26
  • 3Galimberti S,Testi R,Guerrini F et al.The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia,J Chemother,2003,15:374.
  • 4Noskova V,Dzubak P,Kuzmina G et al.In vitro chemoresistance profile and expression function of MDR associated proteins in resistant cell lines derived from CCRF-CEM.K562,A549 and MDA MB 231 parental cells.Neoplasma,2002,49:418.
  • 5Ravindranath Y.Recent advances in pediatric acute lymphoblastie and myeloid leukemia.Curr Opin Oncol,2003,15:23.
  • 6Kasimir-Bauer S,Beelen D,Flasshove M et al.Impact of the expression of P-glycopritein,the multidrug resistance-related protein,bcl-2,mutant p53,and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.Exp Hematol,2002,30:1302.
  • 7Bangur C S,Switzer A,Fan L et al.Identification of genes overexpressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis.Oncogene,2002,21:3814.

二级参考文献2

  • 1曹世龙,肿瘤学新理论与新技术,1997年,437页
  • 2刘振华,肿瘤预后学,1995年,119页

共引文献28

同被引文献10

  • 1付劲蓉,刘文励,周剑锋,周玉峰,徐酉华,金先庆.多药耐药相关基因HV126的电子克隆及在化疗前后白血病细胞中的表达[J].中华医学遗传学杂志,2005,22(2):158-163. 被引量:6
  • 2He T C, Zhou S, da-Costa L T, et al. A simplified system for generating recombinant adenoviruses [J]. Proe Natl Aead Sci U S A, 1998, 95(5) : 2509 -2514.
  • 3Aagaard L, Rossi J J. RNAi therapeutics: principles, prospects and challenges[ J]. Adv Drug Deliv Rev, 2007, 59 (2 - 3 ) : 75 - 86.
  • 4Luo Q, Kang Q, Song W X, et al. Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing[ J]. Gene, 2007, 395(1 -2) : 160 -169.
  • 5Grimm D, Kay M A. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? [ J ]. J Clin Invest, 2007, 117 (12) : 3633 -3641.
  • 6SCOTTO KW, JOHNSON R A. Transcription of the multidrug resistance gene MDR1 : a therapeutic target [ J 1. Mol Interv, 2001, 1(2) :117-125.
  • 7ALEEN J D, SCHINKEL A H. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2) [J]. Mol Cancer Ther, 2002,1 (6) :427-434.
  • 8PENNATI M, FOLINI M, ZAFFARONI N. Targeting survivin in cancer therapy: fulfilled promises and open questions[J].Carcinogenesis, 2007, 28(6):1133-1139.
  • 9AAGAARD L, ROSSI J J. RNAi therapeutics: principles, prospects and challenges[J].Adr Drug Deliv Rev, 2007 ,59 (2/3) : 75 -86.
  • 10QING L, QUAN K, WENXIN S, et al. Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing [ J]. Gene,2007,395 ( 1/2 ) : 160-169.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部